What happens when semaglutide goes generic? Canada finds out

Clinical takeaway: Generic pricing may make subcutaneous semaglutide in Canada affordable enough to use as guidelines already recommend for T2D patients at high cardiorenal risk regardless of glycemic control. US generics for semaglutide aren't expected until after 2032, but access to Canadian generics remains an open question.

The US isn't expected to see generic semaglutide for at least another five years. But Canada is running the experiment now: exclusivity expired there in January 2026 and prices are expected to fall as much as 70% by yearend. New modeling suggests that drop is enough to flip the economics, making injectable GLP-1s cost-effective for the first time in patients with type 2 diabetes and high cardiorenal risk.

Diabetes Canada, consistent with the Canadian Cardiovascular Society and other major guidelines, recommends certain GLP-1 receptor agonists and/or sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults with type 2 diabetes at high cardiovascular or renal risk, with therapy guided by cardiorenal risk rather than A1c alone. Yet GLP-1 coverage under many Canadian public drug plans remains glycemia-driven, often requiring inadequate glycemic control despite cheaper first-line therapy before reimbursement.

An estimated 1.3 to 2.1 million Canadians qualify under these guidelines. Treating them all with GLP-1s would have run $3.35 to $5.31 billion annually at pre-generic prices but is now expected to cost $1.01 to $1.59 billion.

The tipping point comes at a 70% cut, which brings GLP-1 annual cost to $775, comparable to SGLT2is. At that price, GLP-1s are cost-effective against baseline therapy in 99.9% of simulations at a $50,000-per-quality-adjusted-life-year (QALY) threshold. SGLT2is still beat GLP-1 monotherapy in most runs, but adding a GLP-1 to an SGLT2i becomes cost-effective in 95.9% of simulations. Lower complication rates offset part of the drug cost: an estimated $365 in per-patient savings in year one for GLP-1s versus baseline.

Generic GLP-1s are not entirely new territory. Liraglutide went generic in the US in 2024. But semaglutide is the bigger test for access: it is once weekly rather than daily and has shown greater A1c lowering and weight loss than liraglutide in head-to-head diabetes trials.

This analysis used a microsimulation model built on 216 patients with type 2 diabetes and high cardiorenal risk seen at a multispecialty clinic, projecting complications, costs, and QALYs over a lifetime horizon at Quebec formulary prices. The dual-therapy result assumes GLP-1 and SGLT2i benefits are fully complementary when combined.

The authors argue payers should respond by widening reimbursement to dual GLP-1 and SGLT2i therapy for type 2 diabetes with high cardiorenal risk, irrespective of glycemic control. Whether provincial plans move that fast is another question, and the authors note the bill for covering all indicated patients would still exceed $1 billion a year even at generic prices.

"Our results are encouraging and provide further economic justification for the use of these therapies among appropriate patients with type 2 diabetes in Canada, which will significantly improve the quality of life, lower hospitalization costs, and ultimately protect patients from heart failure and kidney disease progression," said co-lead investigator Alton Russell, PhD, of the McGill University School of Population and Global Health.

Source: McNally E, et al (2026 Jul 22) Can J Cardiol. Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes